Wanted pages

From Glioblastoma Treatments
Jump to navigationJump to search

List of non-existing pages with the most links to them, excluding pages which only have redirects linking to them. For a list of non-existent pages that have redirects linking to them, see the list of broken redirects.

Showing below up to 50 results in range #151 to #200.

View ( | ) (20 | 50 | 100 | 250 | 500)

  1. Clinical trials (e.g., advanced cancer study with cachexia, metastatic breast cancer Phase II trial, advanced non-small cell lung cancer trial)‏‎ (1 link)
  2. Common PPI side effects include headache, nausea, diarrhea, abdominal pain, fatigue, and dizziness‏‎ (1 link)
  3. Common side effects associated with Keppra include fatigue, dizziness, and mood changes, but it is generally well-tolerated in the context of brain tumor treatment.‏‎ (1 link)
  4. Data suggests tamoxifen may extend survival for certain glioblastoma patients, with specific outcomes depending on the study and patient demographics‏‎ (1 link)
  5. Deep vein thrombosis, peripheral neuropathy, constipation, somnolence, pyrexia, pain, teratogenicity‏‎ (1 link)
  6. Dose-intense temozolomide alone: Median survival from trial start was 369 days (12.1 months)‏‎ (1 link)
  7. Dry skin, liver problems, increased blood lipid levels, dry mouth, muscle or joint pain, sun sensitivity‏‎ (1 link)
  8. EGFR Inhibitors (Tarceva, Erbitux) in combination with Stupp Protocol‏‎ (1 link)
  9. Early-stage clinical trials, including studies in Brazil for recurrent glioma‏‎ (1 link)
  10. Early clinical evaluation in a small case series‏‎ (1 link)
  11. Early clinical trials and case studies, including a phase 2 clinical trial in Israel (NCT02654041)‏‎ (1 link)
  12. Early clinical trials and observational studies, including phase 2 trials combining Celebrex with conventional cancer treatments‏‎ (1 link)
  13. Early phase trials‏‎ (1 link)
  14. Early results suggest potential efficacy in enhancing chemotherapy response; ongoing trials‏‎ (1 link)
  15. Early to mid-stage clinical trials‏‎ (1 link)
  16. Evidence from colorectal cancer trials shows increased disease-free survival‏‎ (1 link)
  17. Exploratory/Investigational (Specific phase for gliomas not provided)‏‎ (1 link)
  18. Exploratory and Phase 1/2 trials for recurrent glioma in combination with other agents‏‎ (1 link)
  19. Extended survival reported in some clinical trials‏‎ (1 link)
  20. Eye toxicities, especially blurred vision‏‎ (1 link)
  21. Fatigue, dizziness, nausea, mouth irritation‏‎ (1 link)
  22. Fatigue, injection site reaction, erythema, and pain were the most common treatment-related adverse events. No grade 4/5 adverse events reported, indicating a manageable safety profile.‏‎ (1 link)
  23. Fevers, altered mental status shortly after infusion, significant but manageable neurotoxicity‏‎ (1 link)
  24. Few reported; mainly gastrointestinal disturbances‏‎ (1 link)
  25. Gastro-intestinal side effects when administered orally; intranasal administration used to mitigate this‏‎ (1 link)
  26. Gastrointestinal upset, such as diarrhea and nausea; lactic acidosis (rare but serious)‏‎ (1 link)
  27. Generally well-tolerated; bioavailability issues are noted, but can be improved with piperine‏‎ (1 link)
  28. Generally well-tolerated; known side effects include gastrointestinal discomfort and a strong odor. Rare cases of allergic reactions.‏‎ (1 link)
  29. Generally well-tolerated; possible digestive disturbances at high doses‏‎ (1 link)
  30. Generally well-tolerated; potential gastrointestinal issues with long-term use of some NSAIDs. Celebrex designed to minimize COX-1 inhibition and related stomach issues.‏‎ (1 link)
  31. Generally well-tolerated; some reports of gastrointestinal disturbances at high doses‏‎ (1 link)
  32. Generally well-tolerated; specific studies noted minimal impact on adverse event incidence‏‎ (1 link)
  33. Hematologic, gastrointestinal, and hepatic toxicities noted; acceptable safety profile in combination regimens‏‎ (1 link)
  34. Hematological toxicity, nausea, and neurological effects‏‎ (1 link)
  35. Hematological toxicity, nausea, vomiting, and pulmonary toxicity‏‎ (1 link)
  36. Hepatic and pulmonary toxicity, myelosuppression‏‎ (1 link)
  37. Higher rates of thrombocytopenia, neutropenia, and anemia were observed in some studies‏‎ (1 link)
  38. Historical controls suggest a median survival time of 6 months for recurrent GBM‏‎ (1 link)
  39. Hot flashes, joint pain, nausea, increased risk of osteoporosis, fatigue‏‎ (1 link)
  40. Hypercalcemia at high doses of calcitriol; other forms generally safe‏‎ (1 link)
  41. Hypertension, fatigue, hand-foot syndrome, diarrhea, proteinuria, thyroid dysfunction‏‎ (1 link)
  42. Hypertension, proteinuria, and hemorrhage‏‎ (1 link)
  43. Improved in morning dosing, exact data still under investigation.‏‎ (1 link)
  44. Improved progression-free survival in combination with other treatments‏‎ (1 link)
  45. Improvement noted when EGFR inhibitors used in combination treatments, though highly variable‏‎ (1 link)
  46. In a study with newly diagnosed GBM patients, progression-free survival at 6 months was 91% when methadone was added to the standard of care‏‎ (1 link)
  47. In studies, tamoxifen showed potential to improve progression-free survival for GBM patients under specific treatment regimens‏‎ (1 link)
  48. In the glioblastoma study, median overall survival was 9.2 months with low-dose TMZ alone‏‎ (1 link)
  49. In the same glioblastoma study, median overall survival was 17.6 months with low-dose TMZ + VT-122‏‎ (1 link)
  50. Includes diarrhea, nausea, neutropenia, potential for increased risk of birth defects‏‎ (1 link)

View ( | ) (20 | 50 | 100 | 250 | 500)

Retrieved from "http://glioblastomatreatments.wiki:80/index.php?title=Special:WantedPages"